Bespoke Extracts (BSPK) Net Income towards Common Stockholders (2011 - 2025)
Bespoke Extracts (BSPK) reported Net Income towards Common Stockholders of -$78088.0 for Q3 2025, up 71.67% on a YoY basis from -$45487.9 in Q3 2024, and up 61.93% sequentially from -$205106.0 in Q2 2025.
Bespoke Extracts (BSPK) Net Income towards Common Stockholders (2011 - 2025) Analysis & Trends
Bespoke Extracts (BSPK) has 15 years of Net Income towards Common Stockholders data on file, last reported at -$78088.0 in Q3 2025.
- For the quarter ending Q3 2025, Net Income towards Common Stockholders rose 71.67% year-over-year to -$78088.0; the trailing twelve-month figure through Sep 2025 stood at -$730564.0 (up 34.75% YoY), and the FY2024 full-year result was $264358.0, down 27.3% from the prior year.
- Net Income towards Common Stockholders rose to -$78088.0 in Q3 2025, from -$205106.0 in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $3.6 million in Q3 2021 to a low of -$1.1 million in Q3 2022.
- A 5-year average of -$208527.6 and a median of -$299571.0 in 2021 frame the typical range for Net Income towards Common Stockholders.
- Across the five-year window, Net Income towards Common Stockholders surged 212.31% in 2021 and rose 8.59% in 2024, its largest moves.
- Tracing BSPK's Net Income towards Common Stockholders over 5 years: stood at $226984.0 in 2021, then tumbled by 539.51% to -$997626.0 in 2022, then jumped by 73.03% to -$269087.0 in 2023, then jumped by 30.56% to -$186849.0 in 2024, then jumped by 58.21% to -$78088.0 in 2025.
- Business Quant data shows BSPK's Net Income towards Common Stockholders at -$78088.0 in Q3 2025, -$205106.0 in Q2 2025, and -$260521.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -2.35 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Bespoke Extracts | 1.12 Mn | 1.11 Mn | 234,175.00 | -78,088.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -78,088.00 |
| Jun 30, 2025 | -205,106.00 |
| Mar 31, 2025 | -260,521.00 |
| Dec 31, 2024 | -186,849.00 |
| Sep 30, 2024 | -275,613.00 |
| Jun 30, 2024 | -260,895.00 |
| Mar 31, 2024 | -314,118.00 |
| Dec 31, 2023 | -269,087.00 |
| Sep 30, 2023 | -301,529.00 |
| Jun 30, 2023 | -464,915.00 |
| Mar 31, 2023 | -440,620.00 |
| Dec 31, 2022 | -997,626.00 |
| Sep 30, 2022 | -1.13 Mn |
| Jun 30, 2022 | -1.01 Mn |
| Mar 31, 2022 | -972,494.00 |
| Nov 30, 2021 | 226,984.00 |
| Aug 31, 2021 | 3.59 Mn |
| May 31, 2021 | -299,571.00 |
| Feb 28, 2021 | -304,171.00 |
| Nov 30, 2020 | -202,106.00 |